DCAT Value Chain Insights

DCAT Benchmarking Study Provides Insight into Supply-Chain Challenges

How are executives from biopharma companies, CDMOs/CMOs, and suppliers confronting real and potential risks in the wake of new trade policies? A recent DCAT Benchmarking study, conducted prior to...

Pharma Company on the Move: The New AbbVie

Following AbbVie's $63-billion acquisition of Allergan, which closed earlier this month (May 2020), the new AbbVie, reflecting the combined companies, has projected revenues of $50 billion. DCAT...

Q&A with Stephan Haitz, President, CDMO Sales & Marketing at Cambrex

Information
March 9, 2020
Sponsored by Cambrex

Stephan Haitz, President, CDMO Sales & Marketing discusses small molecule trends and how the CDMO industry is constantly evolving to meet the demands and needs of the growing clinical pipeline.

Read More
A Cambrex Webinar- De-Risking the Solid Form Landscape of an API

Information
February 24, 2020
Sponsored by Cambrex

Dr. David Pearson, Chief Scientific Officer of Cambrex Edinburgh, discusses how a full understanding of the crystalline landscape of an active pharmaceutical ingredient (API) molecule can predict...

Read More
Future focus: Our 2020 vision

Information
February 11, 2020
Sponsored by Cambrex

Cambrex eBook: The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021, driven by positive industry trends — many of which our experts commented on in Part 1...

Read More